Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04446117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04446117 · ClinicalTrials.gov record · last posted 2025-12-18

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Study acronym: CONTACT-02
StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started2020-10-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2020-06-22; most recent amendment 2025-12-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-07-13
Status change Recruiting→Active, Not Recruitingv22
2020-06-30
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04446117
Lead Sponsor Exelixis
Collaborators: Roche-Genentech, Takeda
Conditions Metastatic Prostate Cancer, Prostate Adenocarcinoma
Enrollment 575 participants
Start Date 2020-10-19
Primary Completion 2024-04-19 (estimated)
Study Completion 2026-10-16 (estimated)
Updated on ClinicalTrials.gov 2025-12-18